JP2008516898A - チロシンキナーゼ受容体c−fmsを阻害するための4−(4−メチルピペラジン−1−イルメチル)−N−[4−メチル−3−(4−(ピリジン−3−イル)ピリミジン−2−イルアミノ)フェニル]−ベンズアミドの使用 - Google Patents

チロシンキナーゼ受容体c−fmsを阻害するための4−(4−メチルピペラジン−1−イルメチル)−N−[4−メチル−3−(4−(ピリジン−3−イル)ピリミジン−2−イルアミノ)フェニル]−ベンズアミドの使用 Download PDF

Info

Publication number
JP2008516898A
JP2008516898A JP2007535954A JP2007535954A JP2008516898A JP 2008516898 A JP2008516898 A JP 2008516898A JP 2007535954 A JP2007535954 A JP 2007535954A JP 2007535954 A JP2007535954 A JP 2007535954A JP 2008516898 A JP2008516898 A JP 2008516898A
Authority
JP
Japan
Prior art keywords
fms
compound
csf
carcinoma
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007535954A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008516898A5 (cg-RX-API-DMAC7.html
Inventor
アンドレア・ルイス・デウォー
ティモシー・ピーター・ヒューズ
アラン・ブルース・ライオンズ
Original Assignee
メドベット・サイエンス・プロプライエタリー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メドベット・サイエンス・プロプライエタリー・リミテッド filed Critical メドベット・サイエンス・プロプライエタリー・リミテッド
Publication of JP2008516898A publication Critical patent/JP2008516898A/ja
Publication of JP2008516898A5 publication Critical patent/JP2008516898A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007535954A 2004-10-18 2005-10-17 チロシンキナーゼ受容体c−fmsを阻害するための4−(4−メチルピペラジン−1−イルメチル)−N−[4−メチル−3−(4−(ピリジン−3−イル)ピリミジン−2−イルアミノ)フェニル]−ベンズアミドの使用 Pending JP2008516898A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61974404P 2004-10-18 2004-10-18
PCT/AU2005/001602 WO2006042362A1 (en) 2004-10-18 2005-10-17 Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms

Publications (2)

Publication Number Publication Date
JP2008516898A true JP2008516898A (ja) 2008-05-22
JP2008516898A5 JP2008516898A5 (cg-RX-API-DMAC7.html) 2008-12-04

Family

ID=36202610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007535954A Pending JP2008516898A (ja) 2004-10-18 2005-10-17 チロシンキナーゼ受容体c−fmsを阻害するための4−(4−メチルピペラジン−1−イルメチル)−N−[4−メチル−3−(4−(ピリジン−3−イル)ピリミジン−2−イルアミノ)フェニル]−ベンズアミドの使用

Country Status (19)

Country Link
US (1) US20080255139A1 (cg-RX-API-DMAC7.html)
EP (1) EP1804800B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008516898A (cg-RX-API-DMAC7.html)
KR (1) KR20070083705A (cg-RX-API-DMAC7.html)
CN (1) CN101035535A (cg-RX-API-DMAC7.html)
AT (1) ATE492277T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005297321A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0517083A (cg-RX-API-DMAC7.html)
CA (1) CA2580976A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005025514D1 (cg-RX-API-DMAC7.html)
IL (1) IL182419A0 (cg-RX-API-DMAC7.html)
MA (1) MA28946B1 (cg-RX-API-DMAC7.html)
MX (1) MX2007004660A (cg-RX-API-DMAC7.html)
NO (1) NO20072501L (cg-RX-API-DMAC7.html)
NZ (1) NZ554009A (cg-RX-API-DMAC7.html)
RU (1) RU2007118420A (cg-RX-API-DMAC7.html)
TN (1) TNSN07141A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006042362A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200702316B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009058968A2 (en) * 2007-10-31 2009-05-07 Janssen Pharmaceutica N.V. Biomarker for assessing response to fms treatment
EP3246046A4 (en) * 2015-01-13 2018-12-05 Kyoto University Agent for preventing and/or treating amyotrophic lateral sclerosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) * 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
DE60212836T2 (de) * 2001-05-16 2007-01-25 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
US20060052387A1 (en) * 2002-06-26 2006-03-09 Marsh Clay B Organic compounds

Also Published As

Publication number Publication date
RU2007118420A (ru) 2008-11-27
ATE492277T1 (de) 2011-01-15
MA28946B1 (fr) 2007-10-01
DE602005025514D1 (de) 2011-02-03
WO2006042362A1 (en) 2006-04-27
KR20070083705A (ko) 2007-08-24
BRPI0517083A (pt) 2008-09-30
TNSN07141A1 (en) 2008-11-21
CN101035535A (zh) 2007-09-12
EP1804800A4 (en) 2008-03-19
NZ554009A (en) 2010-09-30
CA2580976A1 (en) 2006-04-27
US20080255139A1 (en) 2008-10-16
IL182419A0 (en) 2007-09-20
MX2007004660A (es) 2007-10-17
EP1804800A1 (en) 2007-07-11
ZA200702316B (en) 2008-09-25
EP1804800B1 (en) 2010-12-22
AU2005297321A1 (en) 2006-04-27
NO20072501L (no) 2007-05-15

Similar Documents

Publication Publication Date Title
EP2720696B1 (en) Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
US10314834B2 (en) Therapeutic agent or treatment method for Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) having IKZF1 mutation
Huang et al. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation
Hsu et al. Cordycepin and a preparation from Cordyceps militaris inhibit malignant transformation and proliferation by decreasing EGFR and IL-17RA signaling in a murine oral cancer model
JP2019038821A (ja) Pimキナーゼ阻害剤の組合せ
TW201909921A (zh) 治療組合
TW201806600A (zh) Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
Kim et al. The coffee diterpene kahweol inhibits metastasis by modulating expressions of MMPs and VEGF via STAT3 inactivation
KR20230154793A (ko) 암 치료를 위한 병용 요법
KR20210019422A (ko) 암 치료 방법
JP2011506288A (ja) 白血病の管理における3−(インドリル)−または3−(アザインドリル)−4−アリールマレイミド誘導体の用途
Mirkheshti et al. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer
CA3196283A1 (en) Csf1r kinase inhibitor and use thereof
US20250361307A1 (en) Combination therapies for treating hyperproliferative disorders
US20220025036A1 (en) Use of il-1beta binding antibodies
JP2008501006A (ja) Srcキナーゼ阻害剤AZD0530、および、抗エストロゲン剤またはEGFR−TK−阻害剤を含む組み合わせ製品
JP2018511605A (ja) 慢性骨髄性白血病癌幹細胞の成長抑制用または増殖抑制用の組成物、及びそのスクリーニング方法
EP1804800B1 (en) Use of 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl¨-benzamide to inhibit the tyrosine kinase receptor c-fms
TW202404586A (zh) 癌症的治療或預防用藥物
WO2017090699A1 (ja) ピラジンカルボキサミド化合物を有効成分とするがん免疫治療用医薬組成物、及び/又は、免疫活性化用医薬組成物
US20150141502A1 (en) Inhibition of leukemic stem cells by pp2a activating agents
JP5931876B2 (ja) 多発性嚢胞腎を処置するためのレセプタータイプキナーゼの調節因子の使用
Hedvat Targeting JAK/STAT Signaling for Solid Tumor Therapy
JP2024061699A (ja) Ras遺伝子変異体癌治療薬
Kum β-adrenergic receptor-dependent and-independent effects of propranolol in infantile hemangioma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120619